Form 4 Filing for Robin Howard W at Nektar Therapeutics

This filing details stock transactions by Robin Howard W, President & CEO of Nektar Therapeutics. On December 22, 2025, Howard acquired 21,667 shares of Common Stock through a restricted stock unit (RSU) grant, with these RSUs vesting over four years. Additionally, Howard was granted 86,667 stock options, also vesting over four years, with an exercise price of $43.48 and an expiration date of December 21, 2033. The RSU acquisition was a direct acquisition, while the stock options were also directly acquired. Following these transactions, Howard directly owns 75,912 shares of Common Stock and 86,667 stock options. A separate non-derivative holding indicates 28 shares of Common Stock owned indirectly by spouse.